Literature DB >> 20712798

Redefining thalassemia as a hypercoagulable state.

M Domenica Cappellini1, Irene Motta, Khaled M Musallam, Ali T Taher.   

Abstract

As the life expectancy of beta-thalassemia patients has markedly improved over the last decade, several new complications are being recognized. The presence of a high incidence of thromboembolic events, mainly in thalassemia intermedia patients, has led to the identification of a hypercoagulable state in thalassemia. In this review, the molecular and cellular mechanisms leading to hypercoagulability in thalassemia are highlighted, and the current clinical experience is summarized. Recommendations for thrombosis prophylaxis are also discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20712798     DOI: 10.1111/j.1749-6632.2010.05548.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  23 in total

1.  Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?

Authors:  Giovanna Graziadei; Chiara Refaldi; Wilma Barcellini; Claudia Cesaretti; Elena Cassinero; Khaled M Musallam; Maria Domenica Cappellini
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

Review 2.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).

Authors:  Elliott Vichinsky; Lynne Neumayr; Sean Trimble; Patricia J Giardina; Alan R Cohen; Thomas Coates; Jeanne Boudreaux; Ellis J Neufeld; Kristy Kenney; Althea Grant; Alexis A Thompson
Journal:  Transfusion       Date:  2013-07-25       Impact factor: 3.157

4.  Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.

Authors:  Evangelia Yannaki; Thalia Papayannopoulou; Erica Jonlin; Fani Zervou; Garyfalia Karponi; Angeliki Xagorari; Pamela Becker; Nikoleta Psatha; Ioannis Batsis; Panayotis Kaloyannidis; Varvara Tahynopoulou; Varnavas Constantinou; Asimina Bouinta; Konstantia Kotta; Aglaia Athanassiadou; Achilles Anagnostopoulos; Athanasios Fassas; George Stamatoyannopoulos
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

5.  A thalassaemia intermedia case with concomitant left atrial thrombus.

Authors:  Cem Sahin; Ozcan Basaran; Yasar Topal; Fatih Akin
Journal:  BMJ Case Rep       Date:  2014-06-20

Review 6.  β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.

Authors:  Yelena Ginzburg; Stefano Rivella
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

7.  Thromboelastometry profile in children with beta-thalassemia.

Authors:  Ayşe B Turhan; Özcan Bör; O Meltem Akay; Necat A Akgün
Journal:  Int J Hematol       Date:  2014-03-09       Impact factor: 2.490

8.  Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia.

Authors:  Khaled M Musallam; Maria Domenica Cappellini; John C Wood; Irene Motta; Giovanna Graziadei; Hani Tamim; Ali T Taher
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

9.  Pathophysiology and Clinical Manifestations of the β-Thalassemias.

Authors:  Arthur W Nienhuis; David G Nathan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 10.  Non-transfusion-dependent thalassemias.

Authors:  Khaled M Musallam; Stefano Rivella; Elliott Vichinsky; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.